STOCK TITAN

CorMedix (NASDAQ: CRMD) CCO Seckler files Form 3 showing no ownership

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

CorMedix Inc. filed an initial ownership report for executive Michael David Seckler, its Chief Commercial Officer, showing no beneficial ownership of company securities. This Form 3 states that no non-derivative or derivative securities are beneficially owned at the time of the report. The filing is signed by an attorney-in-fact under a power of attorney, which authorizes them to sign on the officer’s behalf.

Positive

  • None.

Negative

  • None.
SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Seckler Michael David

(Last) (First) (Middle)
C/O CORMEDIX INC.
300 CONNELL DRIVE, SUITE 4200

(Street)
BERKELEY HEIGHTS NJ 07922

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
01/08/2026
3. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Commercial Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
Exhibit 24.1 - Power of Attorney
No securities are beneficially owned.
/s/ Beth Zelnick Kaufman, attorney-in-fact 01/15/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the reporting person in CorMedix (CRMD)'s latest Form 3?

Michael David Seckler is the reporting person. He is identified as an officer of CorMedix Inc. with the title Chief Commercial Officer.

What does this Form 3 for CorMedix (CRMD) disclose about insider ownership?

The Form 3 states in the remarks that no securities are beneficially owned, meaning the reporting officer reports no beneficial ownership of CorMedix securities as of the event date.

What is the event date for this CorMedix (CRMD) Form 3 filing?

The date of event requiring statement is listed as 01/08/2026, which is the reference date for the ownership status disclosed.

Is the CorMedix (CRMD) Form 3 filed by one or multiple reporting persons?

The filing indicates that it is a Form filed by One Reporting Person, referring only to Michael David Seckler.

Who signed the CorMedix (CRMD) Form 3 and in what capacity?

The Form 3 is signed by /s/ Beth Zelnick Kaufman as attorney-in-fact, acting under an Exhibit 24.1 power of attorney for the reporting person.

Does this CorMedix (CRMD) Form 3 show any derivative securities like options or warrants?

The filing’s tables for both non-derivative and derivative securities are effectively empty, and the remarks confirm that no securities are beneficially owned.
Cormedix

NASDAQ:CRMD

CRMD Rankings

CRMD Latest News

CRMD Latest SEC Filings

CRMD Stock Data

552.31M
73.32M
7.56%
46.8%
15.92%
Biotechnology
Pharmaceutical Preparations
Link
United States
BERKELEY HEIGHTS